Episode 6: Primary Care Screening and Treatment of Chronic Kidney Disease Episode 6: Primary Care Screening and Treatment of Chronic Kidney Disease
Drs Sparks and Bansal discuss the screening and treatment for CKD as a primary care physician, including testing, cardiovascular risk, new treatments, and when to refer a patient to a nephrologist.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 14, 2022 Category: Consumer Health News Tags: Nephrology InDiscussion Source Type: news
Ghana: From Deadline to Health Line ... the Story of a Kidney Failure Survivor
[Ghanaian Times] Dialysis, kid-ney transplant, or your life ends in the next five years," said the Doctor. That was the dilemma that Ms Abigail Ashley found herself in when she was diagnosed with chronic kidney disease (CKD) end-stage sometime in August 2007. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 12, 2022 Category: African Health Source Type: news
Dapagliflozin Reduces Hospitalizations Among Patients With CKD
TUESDAY, Dec. 6, 2022 -- For patients with chronic kidney disease (CKD), dapagliflozin reduces the risk for hospitalization, according to a study published online Dec. 6 in the Annals of Internal Medicine.
Meir Schechter, M.D., from the University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 6, 2022 Category: Pharmaceuticals Source Type: news
Does snake envenoming cause chronic kidney disease? A cohort study in rural Sri Lanka - Waiddyanatha S, Silva A, Weerakoon K, Siribaddana S, Isbister GK.
BACKGROUND: There is limited information on the risk of chronic kidney disease (CKD) following snakebite and its relationship with chronic interstitial nephritis in agricultural communities (CINAC). We aimed to investigate CKD in patients with a confirmed ... (Source: SafetyLit)
Source: SafetyLit - November 30, 2022 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Combination Treatment Beneficial in Albuminuric CKD
TUESDAY, Nov. 29, 2022 -- For patients with albuminuric chronic kidney disease (CKD) without diabetes, treatment with the combination of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and sodium-glucose cotransporter-2... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 29, 2022 Category: Pharmaceuticals Source Type: news
'Kidney disease is not just a death sentence, you can live a full life'
Podcaster Dee Moore, who has chronic kidney disease, is using her knowledge to help others. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 28, 2022 Category: Consumer Health News Source Type: news
EMPA-Kidney Seals SGLT2 Inhibitors as'Foundational' for CKD EMPA-Kidney Seals SGLT2 Inhibitors as'Foundational' for CKD
Empagliflozin ' s efficacy in a range of patients with chronic kidney disease in EMPA-Kidney filled evidence gaps and confirmed SGLT2 inhibitors as a key treatment regardless of diabetes status.Medscape Medical News (Source: Medscape Pulmonary Medicine Headlines)
Source: Medscape Pulmonary Medicine Headlines - November 22, 2022 Category: Respiratory Medicine Tags: Nephrology News Source Type: news
After Rejection, Tenapanor for Kidney Disease Faces FDA's Outside Experts
(MedPage Today) -- Does tenapanor hydrochloride (Ibsrela) produce a clinically meaningful effect on serum phosphorus for patients with chronic kidney disease (CKD) on dialysis?
That question will be front and center for independent advisors to... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 15, 2022 Category: American Health Source Type: news
Dialysis Not Always Best Option in Advanced Kidney Disease Dialysis Not Always Best Option in Advanced Kidney Disease
Hospitalization rates were higher in advanced chronic kidney disease (CKD) patients treated with dialysis than those managed conservatively over 2 years of follow-upMedscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 14, 2022 Category: Consumer Health News Tags: Nephrology News Source Type: news
Science Saturday: Seeking a cellular therapy for chronic kidney disease
Every year, more than 130,000 people in the U.S. are diagnosed with end-stage kidney disease, with most cases caused by diabetes. Newer therapies show promise to slow kidney failure rates, but none stop progression to end-stage kidney failure. The research goal of LaTonya Hickson, M.D., is to develop a cell-based therapy that slows — or even stops — diabetic kidney disease from advancing to end-stage kidney disease. "It is going to take a multipronged approach. By utilizing… (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - November 12, 2022 Category: Research Source Type: news
ASN: Empagliflozin Cuts Risk for Progression in CKD
WEDNESDAY, Nov. 9, 2022 -- For patients with chronic kidney disease at risk for progression, the risk for progression of kidney disease or death from cardiovascular causes is reduced with empagliflozin treatment, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 9, 2022 Category: Pharmaceuticals Source Type: news
ASN: Discontinuation of RAS Inhibitors Does Not Increase eGFR in CKD
WEDNESDAY, Nov. 9, 2022 -- For patients with advanced and progressive chronic kidney disease, discontinuation of treatment with renin-angiotensin system (RAS) inhibitors is not associated with a difference in the long-term rate of decrease in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 9, 2022 Category: Pharmaceuticals Source Type: news
New Economic Study: Dapagliflozin Cost-Effective in Kidney Disease New Economic Study: Dapagliflozin Cost-Effective in Kidney Disease
Dapagliflozin is cost-effective for chronic kidney disease compared with standard of care, in the UK, Germany, and Spain, despite the fact that the drug has high acquisition costs, finds a new analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 9, 2022 Category: Consumer Health News Tags: Nephrology News Source Type: news
Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news
CKD Incidence Differs by Race in People With Diabetes
MONDAY, Nov. 7, 2022 -- A high incidence of chronic kidney disease (CKD) persists among U.S. patients with diabetes, with differences seen across racial and ethnic groups, according to a letter to the editor published in the Oct. 13 issue of the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 7, 2022 Category: Pharmaceuticals Source Type: news
